Program

Thursday, January 21

7:45 AM–9:30 AM
Welcome and General Session 1: How We Should Be Screening and Novel Screening Techniques
Amitabh Chak, MD—Chair University Hospitals Case Medical Center
Cathy Eng, MD, FACP The University of Texas MD Anderson Cancer Center
Risk versus Cost: Should We Be Screening for Barrett’s Esophagus?
Gary W. Falk, MD, MS Perelman School of Medicine at University of Pennsylvania
Pro Kenneth Wang, MD Mayo Clinic
Con Naohisa Yahagi, MD, PhD Keio University School of Medicine
Screening for Squamous Cell Carcinoma: The Japanese Perspective
William Grady, MD Fred Hutchinson Cancer Research Center
Applications of Biomarkers in Screening and Surveillance
Panel Question and Answer

10:00 AM–11:00 AM
Keynote Lectures: Microbial Pathogens and Malignancy
Paul M. Lieberman, PhD The Wistar Institute
Epstein-Barr Virus Biology and its Carcinogenic Mechanisms
Keith T. Wilson, MD Vanderbilt University Medical Center
Helicobacter Pylori–Induced Gastric Carcinogenesis: Molecular Mechanisms and Opportunities for Chemoprevention
Panel Question and Answer

11:00 AM–12:30 PM
General Session 2: Is There an Optimal Chemotherapy Regimen for Advanced Gastric Cancer? (ARS)
Manish A. Shah, MD—Co-Chair Weill Cornell Medical College
Michael J. Weyant, MD—Co-Chair University of Colorado, Denver
ABSTRACT 1: Prospective randomized phase II study of FOLFIRI versus FOLFOX7 in advanced gastric adenocarcinoma: A Chinese Western Cooperative Gastrointestinal Oncology Group study.
First Author: Feng
Case Presentation
Salah-Eddin Al-Batran, MD Institute of Clinical Cancer Research, UCT University Cancer Center Frankfurt
Optimal Therapy for Localized Disease
Yoon-Koo Kang, MD, PhD Asan Medical Center, University of Ulsan College of Medicine
Optimal Therapy for Advanced Disease
Holly Gwen Prigerson, PhD Weill Cornell Medical College
Palliative Care and Third-Line Chemotherapy
Panel Question and Answer

12:30 PM–2:00 PM
Poster Session A: Cancers of the Esophagus and Stomach
Posters by Topic
Prevention, Diagnosis, and Screening: Poster Boards F8–G18
Translational Research: Poster Boards F6, G19–J11
Multidisciplinary Treatment: Poster Boards F1–F5, F7, J12–N22, O3–O16

12:30 PM–2:00 PM
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach
Translational Research: Poster Boards O1–O2
Multidisciplinary Treatment: Poster Boards O3–O16
2:00 PM–3:30 PM
Oral Abstract Session: Cancers of the Esophagus and Stomach
Prajnan Das, MD, MS, MPH—Co-Chair The University of Texas MD Anderson Cancer Center
Ulysses Ribeiro, MD, PhD—Co-Chair University of São Paulo

**ABSTRACT 3:** NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma.
First Author: Somnath Mukherjee

**ABSTRACT 4:** Multicenter double-blind randomized phase II: FOLFOX + ziv-aflibercept/placebo for patients (pts) with chemo-naive metastatic esophagogastric adenocarcinoma (MEGA).
First Author: Peter C. Enzinger

**ABSTRACT 5:** A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC).
First Author: Yoon-Koo Kang

**Discussion:** Daniel V.T. Catenacci, MD The University of Chicago

**ABSTRACT 6:** Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.
First Author: Dung T. Le

**ABSTRACT 7:** Updated results for the advanced esophageal carcinoma cohort of the phase Ib KEYNOTE-028 study of pembrolizumab (MK-3475).
First Author: Toshihiko Doi

**Discussion:** Marcus H. Moehler, MD, PhD Johannes-Gutenberg University Mainz

Panel Question and Answer

4:00 PM–5:30 PM
General Session 3: Multimodal Approaches for Advanced Gastroesophageal Junction Cancers—Challenging Cases from the United States and Europe versus Asia (ARS)
Daniel V.T. Catenacci, MD—Co-Chair The University of Chicago
Heinz-Josef Lenz, MD, FACP—Co-Chair USC Norris Comprehensive Cancer Center

**ABSTRACT 2:** A western validation of a novel gastric cancer prognostic model using American data.
First Author: Bryan S. Goldner

Case Presentation
Yuko Kitagawa, MD, PhD, FACS Keio University School of Medicine

Eastern Perspective: Surgeon
Atsushi Ohtsu, MD, PhD Exploratory Oncology Research & Clinical Trial Center, National Cancer Center

Eastern Perspective: Medical Oncologist
Prajnan Das, MD, MS, MPH The University of Texas MD Anderson Cancer Center

Western Perspective: Radiation Oncologist
Brian D. Badgwell, MD The University of Texas MD Anderson Cancer Center

Western Perspective: Surgeon
Jennifer Rachel Eads, MD University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University

Western Perspective: Medical Oncologist

Panel Question and Answer

5:30 PM–7:00 PM
Poster Session A: Cancers of the Esophagus and Stomach (Continued) and Networking Reception
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach (Continued) and Networking Reception.
Poster Walk Leader: Eric Van Cutsem, MD, PhD University Hospital Gasthuisberg
Poster Walk Leader: Ulysses Ribeiro, MD, PhD University of São Paulo
6:00 PM–7:00 PM
**Breakout Session: Mechanical Palliation in Advanced Gastroesophageal Cancer**
Ulysses Ribeiro, MD, PhD University of São Paulo
*Surgery*
Felice Schnoll-Sussman, MD Weill Cornell Medical College, New York-Presbyterian Hospital
*Endoscopic Therapy*
**Panel Question and Answer**

**Breakout Session: Rare Tumors of the Upper GI Tract**
Jennifer Rachel Eads, MD University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University
*GIST and Neuroendocrine Tumors*
Juan W. Valle University of Manchester, The Christie Hospital
*Bile Duct Cancer*
**Panel Question and Answer**

---

**Friday, January 22**

6:55 AM–7:55 AM
**Breakout Session: Fighting Cancer With Big Data—Using Population Data to Improve Outcomes**
Margaret T. Mandelson, PhD, MPH Virginia Mason Medical Center
*Fighting Cancer with Big Data: Using Population Data to Improve Outcomes*
**Panel Question and Answer**

**Breakout Session: Recent Advances in Treatment of Neuroendocrine Tumors**
Pamela L. Kunz, MD Stanford University School of Medicine
*New Options for Neuroendocrine Tumors: Results of Recent Trials*
Lisa Bodei, MD European Institute of Oncology
*Rationale for Peptide Receptor Radiation Therapy*
Dik J. Kwakkeboom, MD, PhD Erasmus University Medical Center
*The Rotterdam Experience: Peptide Receptor Radionuclide*
**Panel Question and Answer**

7:55 AM–9:30 AM
**Welcome and General Session 4: Innovative Approaches to Hepatopancreatobiliary Disease (ARS)**
Sarah E. Hoffe, MD—Co-Chair Moffitt Cancer Center
Shishir K. Maithel, MD, FACS—Co-Chair Winship Cancer Institute of Emory University
George A. Fisher, MD, PhD Stanford University School of Medicine
**Case Presentation #1**
Robert A. Wolff, MD The University of Texas MD Anderson Cancer Center
*Pro: Neoadjuvant Therapy*
Nipun B. Merchant, MD, FACS University of Miami Medical Center
*Con: Neoadjuvant Therapy*
**Case Question Follow Up and Rebuttals**
**Case Presentation #2**
Joseph M. Herman, MD, MSc Johns Hopkins University School of Medicine
*Stereotactic Body Radiation Therapy as Neoadjuvant Therapy*
Robert C.G. Martin, II, MD, PhD, FACS University of Louisville
*Innovative Surgical Option: Irreversible Electroporation*
**Panel Question and Answer**

10:00 AM–11:00 AM
**Keynote Lecture: Inflammatory Networks and Cancer Immune Surveillance**
Robert H. Vonderheide, MD, DPhil Abramson Cancer Center of the University of Pennsylvania
*Inflammatory Networks and Cancer Immune Surveillance*
**Panel Question and Answer**
11:00 AM–12:30 PM

**General Session 5: Pancreatic Cancer—An International Dialogue About Patterns of Care and Their Impact on Outcomes**

Jorge Gallardo, MD—Co-Chair Centro Oncología Clínica Alemana
Vincent J. Picozzi, MD, MMM—Co-Chair Virginia Mason Medical Center

**ABSTRACT 191:** Resected pancreatic cancer (PC): Impact of adjuvant therapy (Rx) at a high-volume center (HVC) on overall survival (OS).

First Author: Margaret T. Mandelson

**Introduction**

James L. Abbruzzese, MD, FACP Duke University Academic Center
Michael Seiden, MD, PhD McKesson Specialty Health Community Perspective
Ricardo Rossi, MD Centro Oncología Clínica Alemana International Perspective
Wolff H. Schmiegel, MD, PhD Ruhr-University Bochum International Perspective

Panel Question and Answer

12:30 PM–2:00 PM

**Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract Posters by Topic**

Prevention, Diagnosis, and Screening
Translational Research
Multidisciplinary Treatment

12:30 PM–2:00 PM

**Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract Posters by Topic**

Prevention, Diagnosis, and Screening
Multidisciplinary Treatment
Translational Research:

12:45 PM–1:45 PM

**Poster Walks**

**Poster Walk Leader:** Boris Blechacz, MD, PhD The University of Texas MD Anderson Cancer Center

**Poster Walk Leader:** Tushar Patel, MBChB Mayo Clinic

2:00 PM–3:30 PM

**Oral Abstract Session: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract**

Jordan Berlin, MD—Co-Chair Vanderbilt-Ingram Cancer Center
Vincent J. Picozzi, MD, MMM—Co-Chair Virginia Mason Medical Center

**ABSTRACT 193:** Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study.

First Author: Eric Van Cutsem

**ABSTRACT 194:** NETTER-1 phase III: Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177-Lu-Dotatate.

First Author: Jonathan R. Strosberg

**ABSTRACT 195:** PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers.

First Author: Dung T. Le (*Poster Session B, Board A5*)

**Discussion:** Bertram Wiedenmann, MD, PhD Charité University Hospital, Berlin

**ABSTRACT 197:** Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC).

First Author: Lorenza Rimassa

**Discussion:** Boris Blechacz, MD, PhD The University of Texas MD Anderson Cancer Center

Panel Question and Answer
4:00 PM–5:30 PM
**General Session 6: Hepatocellular Carcinoma Tumor Board (ARS)**
Steven N. Hochwald, MD—Co-Chair Roswell Park Cancer Institute
Tushar Patel, MBChB—Co-Chair Mayo Clinic

**ABSTRACT 192:** Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).
First Author: Ghassan K. Abou-Alfa
Julie Heimbach, MD Mayo Clinic

**Transplant Surgeon**
Theodore S. Hong, MD Massachusetts General Hospital

**Radiation Oncologist**
David C. Madoff, MD, FSIR, FACR Weill Cornell Medical College

**Interventional Oncologist**
Richard S. Finn, MD Ronald Regan UCLA Medical Center

**Medical Oncologist**

**Panel Question and Answer**

5:30 PM–7:00 PM
**Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract (Continued) and Networking Reception**

5:30 PM–7:00 PM
**Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract (Continued) and Networking Reception**

6:00 PM–7:00 PM
**Breakout Session: Perspectives on Physician Aid in Dying (ARS)**
George A. Fisher, MD, PhD—Chair Stanford University School of Medicine
Lynne Patricia Taylor, MD Virginia Mason Medical Center

**Death with Dignity: Fulfilling a Need**
Kavitha Ramchandran, MD Stanford University School of Medicine

**Potential Pitfalls in the Process**

**Panel Question and Answer**

---

**Saturday, January 23**

6:55 AM–7:55 AM
**Breakout Session: Multiplex Approach to Colon Cancer Testing—is It Ready for Prime Time?**
James M. Ford, MD Stanford University School of Medicine

**Multiplex Approach to Colon Cancer Testing: Is It Ready for Prime Time?**

**Panel Question and Answer**

**Breakout Session: The Importance of Recognizing Microsatellite Instability Tumors—Cancer Prevention and New Options for Treatment**
Zsofia Kinga Stadler, MD Memorial Sloan Kettering Cancer Center

**The Importance of Microsatellite Instability Screening**
Dung T. Le, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

**PD1 Antibody for Microsatellite Instability–High Tumors**

**Panel Question and Answer**
7:00 AM–7:55 AM
**Poster Session C: Cancers of the Colon, Rectum, and Anus**
*Posters by Topic*
Prevention, Diagnosis, and Screening
Multidisciplinary Treatment
Translational Research

7:00 AM–7:55 AM
**Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus**
*Posters by Topic*
Translational Research
Multidisciplinary Treatment

7:55 AM–9:30 AM
**Welcome and General Session 7: Controversies in Screening and Surveillance in Colorectal Cancer**
Andrew T. Chan, MD, MPH—Co-Chair Massachusetts General Hospital
Rodrigo Jover, MD, PhD—Co-Chair Alicante General University Hospital
Bertram Wiedenmann, MD, PhD Charité University Hospital, Berlin

**ABSTRACT 488:** Early detection of colorectal neoplasia: Combination of eight cancer-associated blood-based protein biomarkers.
First Author: Ib J. Christensen
Linda Rabeneck, MD, MPH, FRCPC Cancer Care Ontario and The University of Toronto

**Colorectal Cancer Screening: Global Disparities in Resources and Approaches**
Michael Bretthauer, MD, PhD University of Oslo

**Controversies in Surveillance After Adenoma and Colorectal Cancer Diagnosis**
Douglas K. Rex, MD, MACP, MACG, FASGE, AGAF Indiana University School of Medicine

**Novel Endoscopic Screening Approaches**
Carolyn C. Compton, MD, PhD Arizona State University and Mayo Clinic

**Complexities of Pathologic Assessment of Adenomas and Serrated Polyps**
Panel Question and Answer

10:00 AM–11:00 AM
**Keynote Lectures: Global Overview of Colorectal Cancer—Past, Present, and Future**
David Cunningham, MD, FRCP, FMedSci The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research

**Global Overview of Colon Cancer**
Daniel G. Haller, MD, FACP, FRCP Abramson Cancer Center of the University of Pennsylvania

**Global Overview of Rectal Cancer**
Panel Question and Answer

11:00 AM–12:30 PM
**General Session 8: Diverse International Perspectives on the Work-up and Management of Rectal Cancer**
Regina G.H. Beets-Tan, MD, PhD—Co-Chair The Netherlands Cancer Institute
Vincenzo Valentini, MD, Professor—Co-Chair Università Cattolica S. Cuore

**Case Presentation**
Gina Brown, MD The Royal Marsden NHS Foundation Trust
*Endoscopic Ultrasonography versus MRI for Staging and Response Evaluation*
Claus Roedel, MD University of Frankfurt
*Short-Course versus Long-Course Chemoradiation Therapy*
Philip Paty, MD Memorial Sloan Kettering Cancer Center
*Surgical Options for Low Rectal Cancer*
Bengt Glimelius, Professor, MD, PhD Uppsala University
*Chemotherapy for Rectal Cancer: When Is It Beneficial?*
Panel Question and Answer
12:30 PM–2:00 PM  
**Poster Session C: Cancers of the Colon, Rectum, and Anus**

12:30 PM–2:00 PM  
**Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus**

1:00 PM–1:45 PM  
**Poster Walks**  
Poster Walk Leader: Pamela L. Kunz, MD Stanford University School of Medicine  
Poster Walk Leader: Sarah E. Hoffe, MD Moffitt Cancer Center

2:00 PM–3:30 PM  
**Oral Abstract Session: Cancers of the Colon, Rectum, and Anus**  
Daniel Chang, MD—Co-Chair Stanford University School of Medicine  
Eunice L. Kwak, MD, PhD—Co-Chair Massachusetts General Hospital

**ABSTRACT 489:** Neoadjuvant chemoradiation for fixed cT3 or cT4 rectal cancer: Results of a Polish II multicentre phase III study.  
First Author: Krzysztof Bujko

**ABSTRACT 490:** ACCORD12/0405-Prodige 2 phase III trial neoadjuvant treatment in rectal cancer: Results after 5 years of follow-up.  
First Author: Eric Francois

**ABSTRACT 491:** The incidence of secondary pelvic tumors after previous (chemo)radiation for rectal cancer.  
First Author: Anouk J.M. Rombouts *(Poster Session C, Board A4)*

**Discussion:** Claus Roedel, MD University of Frankfurt

**ABSTRACT 492:** Overall response rate (ORR) in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).  
First Author: Johanna C. Bendell

**ABSTRACT 493:** MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC).  
First Author: Heinz-Josef Lenz

**Discussion:** Wells A. Messersmith, MD University of Colorado Cancer Center

**Panel Question and Answer**

4:00 PM–5:30 PM  
**General Session 9: Difficult Cases in Rectal Cancer (ARS)**  
Karyn A. Goodman, MD, MS—Co-Chair University of Colorado School of Medicine  
Diane L. Reidy, MD—Co-Chair Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College

**Case Presentation**  
Neil Howard Segal, MD, PhD Memorial Sloan Kettering Cancer Center

**Medical Oncologist Perspective**  
Nancy N. Baxter, MD, PhD, FRCS St. Michael’s Hospital

**Surgeon Perspective**  
Lisa A. Kachnic, MD, FASTRO Vanderbilt University Medical Center

**Radiation Oncologist Perspective**  
Alan P. Venook, MD University of California, San Francisco

**Medical Oncologist Perspective**  
**Panel Question and Answer**